Bruker (BRKR) investor relations material

Executive summary

• Q2 2026 revenue increased 5.2% year-over-year to $838.5M, with organic growth of 2.8% and strong bookings in scientific instruments, semiconductor tools, energy research, and biopharma markets.

• Non-GAAP EPS surged 53% to $0.49, while GAAP results reflected a $(0.41) loss per share due to a $134.9M goodwill impairment charge.

• Margin expansion driven by cost actions, tariff refunds, and favorable mix; non-GAAP gross margin reached 52.1%, operating margin 14.1%.

• Bookings in scientific instruments and deep tech segments up 10%+ year-over-year; biopharma and semiconductor orders showed robust growth.

• New operating structure consolidates divisions, expected to drive further cost reductions and innovation.

Financial highlights

• Q2 2026 reported revenue: $839M, up 5.2% year-over-year; organic growth 2.8%.

• Non-GAAP gross margin: 52.1% (+350 bps); non-GAAP operating margin: 14.1% (+510 bps); GAAP gross margin: 49.6%.

• Non-GAAP diluted EPS: $0.49, up from $0.32 in Q2 2025; GAAP net loss attributable to shareholders: $62.9M.

• H1 2026 revenue: $1.66B (+3.9%); non-GAAP operating margin improved to 12.2%.

• Operating cash flow improved by $50M year-over-year; free cash flow up $43M.

Outlook and guidance

• FY 2026 reported revenue expected at $3.54–$3.57B, 3–4% growth year-over-year; organic growth guidance 1–2%.

• Non-GAAP EPS guidance: $2.10–$2.15, representing 15–17% growth; guidance reflects a ~$0.10 per share currency headwind.

• Non-GAAP operating margin expansion of 250–300 bps expected.

• Q3 2026 organic revenue expected flat to slightly up; Q4 expected to see strong sequential and year-over-year growth.

• Management expects sufficient liquidity for at least the next twelve months.